Uncategorized
Iluvien granted marketing authorization in Sweden
The Swedish Medical Products Agency has granted marketing authorization to Iluvien for the treatment of chronic diabetic macular edema-associated vision impairment in patients unresponsive to other available therapies, according to an Alimera Sciences press release.The approval in Sweden marks the third granting Iluvien (190 mcg intravitreal implant in applicator) marketing approval under the company’s Repeat-Use Procedure application.